Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report
© Kaczorowska-Hac et al.; licensee BioMed Central Ltd. 2012
Received: 25 March 2012
Accepted: 30 May 2012
Published: 10 August 2012
Valproic acid is a commonly used anti-epileptic drug. Hematological toxicities are among the occasionally observed adverse effects of this medication.
We present the case of a 13-year-old Caucasian boy who demonstrated mild anemia 12 months after the introduction of valproic acid therapy. A bone marrow biopsy revealed maturation arrest of proerythroblasts.
Prompt diagnosis and valproic acid discontinuation resulted in the patient’s recovery.
KeywordsValproic acid Anemia Child
Aplastic anemia, pure red cell aplasia, macrocytosis, leukopenia and thrombocytopenia are some of the hematological adverse effects of valproic acid therapy cited in the literature [1, 2]. Some of these effects can lead to life-threatening complications. We present the case of a 13-year-old Caucasian boy who presented with mild macrocytic anemia 12 months after the introduction of valproic acid therapy. A bone marrow biopsy revealed maturation arrest of proerythroblasts. Spontaneous recovery was observed after the patient’s therapy was discontinued.
A 13-year-old Caucasian boy admitted to the Hematology Department at our institution was diagnosed with anemia. Eight years prior to the admission he had been diagnosed with epilepsy. He was treated with 10 mg lamotrigine per day, which was withdrawn after one year because the seizures had ceased. Six years after the anticonvulsant therapy was discontinued a review electroencephalogram (EEG) revealed many synchronic epileptiform changes, that is, sharp waves and spikes. In spite of the fact that there were no reported seizures during the above-mentioned period, 20mg/kg/day valproic acid therapy was introduced.
After 12 months of therapy, during a routine visit, the neurologist noticed the patient presented with pallor. He did not report any other ailments and was leading an active life. His laboratory parameters were as follows: hemoglobin (Hb), 9.2g/dl; red blood cells (RBCs), 2.71 × 1012/L; mean corpuscular volume (MCV), 100 fl; mean corpuscular hemoglobin (MCH), 33.9pg; mean corpuscular hemoglobin concentration (MCHC), 34g/dl; platelets, 321 × 109/L; and white blood cells (WBCs), 4300 × 106/L. The only other medication taken by the patient was loratadine for his pollen allergy. Both the patient and his mother denied any exposure to environmental toxins, taking other medications or drugs, drinking alcohol, or smoking cigarettes. They confirmed full adherence to the therapy. The patient also denied having had any respiratory tract infections in the period preceding examination.
Laboratory findings of the patient at the admission
14 to 18g/dl
Red blood cells
2.76 × 1012/L
4.7 to 6.1 × 1012/L
42% to 52%
0.5% to 2.0%
Mean corpuscular volume
79 to 95fl
Mean corpuscular hemoglobin concentration
33 to 38g/dl
Mean corpuscular hemoglobin
White blood cells
4520 × 106/L
4500 to 11,000 × 106/L
1.69 × 106/L
1.9 to 8.0 × 106/L
311 × 109/L
130 to 400 × 109/L
31 to 144μg/dl
21.81 to 274.66ng/ml
189 to 883pg/ml
2.34 to 17.56ng/ml
0.5 to 1.0mg/dl
0 to 55U/L
5 to 34U/L
125 to 220U/L
0.0 to 5.0mg/L
8 to 36mU/ml
50 to 100mg/L
The patient is still without anticonvulsant therapy and does not have any neurological symptoms.
Valproic acid is a widely used anti-convulsant agent and is also clinically effective as a mood stabilizer in the treatment of manic depression. However, it may induce a variety of side effects, such as bone marrow toxicity, which may lead to life-threatening complications. Severe hematological complications such as thrombocytopenia, leukopenia, aplastic anemia, and pure red cell aplasia have been described [3–6]. Several cases of these adverse effects have been noted in the literature. Nasreddine et al.  reported that, of 851 patients who were treated with valproic acid, 17.7% experienced at least one episode of thrombocytopenia. Rahman et al.  reported that, of 131 children and adolescents treated with valproic acid, 26% experienced leukopenia. Although Handoko et al.  reported that the use of valproic acid is associated with a ninefold risk of aplastic anemia, Zaccara et al.  confirmed that the incidence of pure red cell aplasia is sporadic.
Our 13-year-old patient was on a standard dose of valproic acid for merely 12 months. He reported none of the above-described ailments and did not present with any abnormalities except for the marked pallor. Mild macrocytic anemia was confirmed by a routine blood test. Common causes of this condition, such as vitamin B12 and folic acid deficiency, were excluded. There was no evidence of valproate overdose, and tests for infections were negative. Moreover, there was no evidence of any influence of loratadine on the development of anemia. The bone marrow biopsy showed a diminished number of orthochromatic erythroblasts, but proerythroblasts were within the normal values. The myeloid:erythroid ratio was within the reference range. The patient’s recovery was spontaneous after the discontinuation of the medication, and his blood parameters improved over a five month observation period.
When we reviewed the literature, we found that the population of patients stricken with valproic acid hematological complications seemed to be heterogenic. Some of the patients previously documented had undergone relatively longer treatment . Some of them had been treated with higher doses of valproate , and some had been taking other anticonvulsants  or other additional medications . Our patient presented with normocellular bone marrow with qualitative abnormalities of erythropoiesis, whereas other authors have presented cases of patients with severe abnormalities of the bone marrow, such as hypocellularity, myelodysplasia, and changes resembling promyelocytic leukemia as well [1, 3, 12]. Thus, we believe that valproate caused dyserythropoiesis in our patient, resulting in mild macrocytic anemia.
It has previously been confirmed in a microarray analysis by Chateauvieux et al.  that valproic acid is able to alter hematopoiesis by inhibition of erythroid differentiation in the experimental K562 cell lineage. We suspected that the anticonvulsant had a similar impact on erythroid precursors in our patient. This led to the decision to withdraw the valproate, resulting in a successful and lasting outcome.
Neurologists should be aware of the hematological adverse effects of valproic acid. Regular testing of hematological parameters is essential in patients on such treatment.
Written informed consent was obtained from the patient’s legal guardian for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- The T, Kolla R, Dawkins F, Trouth AJ: Pure red cell aplasia after 13 years of sodium valproate, and bone marrow suppression after 17 years of carbamazepine. PLoS Med. 2004, 1: e51-10.1371/journal.pmed.0010051.View ArticlePubMedPubMed CentralGoogle Scholar
- Zaccara G, Franciotta D, Perucca E: Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007, 48: 1223-1244. 10.1111/j.1528-1167.2007.01041.x.View ArticlePubMedGoogle Scholar
- Acharya S, Bussel JB: Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000, 22: 62-65. 10.1097/00043426-200001000-00012.View ArticlePubMedGoogle Scholar
- Handoko KB, Souverein PC, van Staa TP, Meyboom RH, Leufkens HG, Egberts TC, van den Bemt PM: Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006, 47: 1232-1236. 10.1111/j.1528-1167.2006.00596.x.View ArticlePubMedGoogle Scholar
- Kanada J, Chonabayashi K, Watanabe M, Arima N, Tsudo M: Successful treatment with cyclosporine of sodium valproate-induced pure red cell aplasia] [in Japanese. Rinsho Ketsueki. 2005, 46: 1114-1117.Google Scholar
- Farkas V, Szabó M, Rényi I, Kohlhéb O, Benninger C: Temporary pure red-cell aplasia during valproate monotherapy: clinical observations and spectral electroencephalographic aspects. J Child Neurol. 2000, 15: 485-487. 10.1177/088307380001500713.View ArticlePubMedGoogle Scholar
- Nasreddine W, Beydoun A: Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008, 49: 438-445. 10.1111/j.1528-1167.2007.01429.x.View ArticlePubMedGoogle Scholar
- Rahman A, Mican LM, Fischer C, Campbell AH: Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009, 43: 822-830. 10.1345/aph.1L617.View ArticlePubMedGoogle Scholar
- Klimaszyk D, Łukasik-Głebocka M: Pancytopenia in the course of acute valproic acid poisoning: case report [in Polish]. Przegl Lek. 2011, 68: 539-542.PubMedGoogle Scholar
- Hemingway C, Leary M, Riordan G, Schlegal G, Walker K: The effect of carbamazepine and sodium valproate on the blood and serum values of children from a Third-World environment. J Child Neurol. 1999, 14: 751-753. 10.1177/088307389901401114.View ArticlePubMedGoogle Scholar
- Antoniou T, Gough K, Yoong D, Arbess G: Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis. 2004, 38: e38-e40. 10.1086/381760.View ArticlePubMedGoogle Scholar
- Bartakke S, Abdelhaleem M, Carcao M: Valproate-induced pure red cell aplasia and megakaryocyte dysplasia. Br J Haematol. 2008, 141: 133-10.1111/j.1365-2141.2008.06979.x.View ArticlePubMedGoogle Scholar
- Chateauvieux S, Eifes S, Morceau F, Grigorakaki C, Schnekenburger M, Henry E, Dicato M, Diederich M: Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem Pharmacol. 2011, 81: 498-509. 10.1016/j.bcp.2010.11.011.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.